Why trending categories should be overshoot
When a product category goes viral, it hardly passes without the attention of regulators. The FDA, FTC, CPSC, and other agencies actively track the trending markets, and enforcement activity usually tracks peaks of demand.
The most frequent categories that suffer regulatory questioning are:
- Fitness and wellness products and health supplements.
- Aids and Metabolic drugs help to lose weight.
- Toys and safety gear for children.
- Electronics appliances (particularly imported items)
- Cosmetics and skincare making treatment claims.
Healthcare case: every seller needs to know
For example, GLP-1-based drugs such as Ozempic and Wegovy have seen immense consumer demand. However, reports of severe side effects have also led to increased regulatory scrutiny and a wave of lawsuits against manufacturers, with firms like Bursor & Fisher, P.A. representing affected patients in complex pharmaceutical litigation.
For online sellers, this serves as a cautionary signal: even indirect participation in such high-demand categories through supplements, marketing claims, or adjacent products can expose businesses to regulatory and legal risk if not handled carefully.
What does this imply for the online sellers?
Even more related items, such as supplements that are sold as having a metabolic supportive effect, can creep into drug-claim territory just because of the wording.
Health Products Compliance Guidance by the FTC clarifies that it is a violation of claims about disease, regardless of the intention of the seller, without FDA approval.
In this category, regulatory fines have ranged from 10,000 to a million dollars per offense.
What to do before listing in any health-adjacent categorization
- Check each word of your product copy – even supplier descriptions you have copy-pasted.
- Draw the line between structure/function claims (supports healthy joints) and disease claims (treats arthritis); only the former can be accepted in general.
- Get a reference to a regulatory attorney to do a pre-launch review – it is a lot less than a compliance violation.